Amgen (NASDAQ:AMGN – Get Free Report) had its price objective boosted by Guggenheim from $288.00 to $305.00 in a research note issued on Thursday,MarketScreener reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Guggenheim’s target price indicates a p... Read more
Markets Daily - Nov 07
